Acucela prices its initial public offering on the Tokyo Stock Exchange at $162M.

Vision training can restore some of the sight lost to glaucoma.

The new method to produce stem cells has run into difficulties in the form of image irregularities and the failure of other labs to reproduce the findings.

Previous studies linked aspirin use with age-related macular degeneration, but new data suggest otherwise: aspirin is innocent of all charges.

If you’re aged over 68 years, then statins significantly reduce your risk of developing AMD; it has no impact on younger age groups.

The finding that the core of the trabecular meshwork is an extension of Dua’s layer may have significance in understanding and treating glaucoma.

Mice that take exercise exhibit slower retinal degeneration than those that don’t. It could work for people too.

Our cataloging of the major eye diseases is insightful, even though impact factor analysis is flawed.

Can you envisage a future in which deploying a tiny cell-spraying device during vitreoretinal surgery reverses years of retinal cell death? Keith Martin can.

You can’t predict the future, but a lot can be learned by analyzing what happened in the past.